Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1Breast 1

Conditions

Leukemia, Myeloid, Acute 12Multiple Myeloma 9Lymphoma 8Breast Neoplasms 8Lymphoma, Non-Hodgkin 7Hodgkin Disease 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Lymphoma, Large B-Cell, Diffuse 4Central Nervous System Neoplasms 4Burkitt Lymphoma 4Sarcoma 3Medulloblastoma 3Leukemia 3Brain Neoplasms 3Anemia, Refractory, with Excess of Blasts 3Wilms Tumor 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Retinoblastoma 2Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Malignant mesenchymal tumor 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2

Interventions

pegfilgrastim 1MYL-1401H 1Long-Term Synaptic Depression 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Chemotherapy-Induced Febrile Neutropenia × Granulocyte Colony-Stimulating Factor × Clear all
NCT02467868 2022-02-14

Efficacy and Safety Study With MYL-1401H and Neulasta

Viatris Inc.

Phase 3 Completed
193 enrolled
BreastClassical hematology

Breast Neoplasms, Neutropenia, Chemotherapy-Induced Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡